SG Americas Securities LLC Sells 8,815 Shares of TransMedics Group, Inc. $TMDX

SG Americas Securities LLC lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 56.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,910 shares of the company’s stock after selling 8,815 shares during the quarter. SG Americas Securities LLC’s holdings in TransMedics Group were worth $687,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group in the 3rd quarter worth about $29,000. Allworth Financial LP increased its position in TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the period. FNY Investment Advisers LLC bought a new position in shares of TransMedics Group during the third quarter valued at $34,000. Parallel Advisors LLC increased its holdings in TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the period. Finally, Hantz Financial Services Inc. lifted its stake in shares of TransMedics Group by 196.2% in the fourth quarter. Hantz Financial Services Inc. now owns 311 shares of the company’s stock worth $38,000 after acquiring an additional 206 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the transaction, the director owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by company insiders.

TransMedics Group Price Performance

Shares of TMDX traded down $0.73 during midday trading on Tuesday, hitting $70.50. 27,762 shares of the company traded hands, compared to its average volume of 1,102,058. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The firm has a market cap of $2.44 billion, a P/E ratio of 16.03 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The stock has a 50-day moving average of $74.20 and a 200-day moving average of $107.75.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. TransMedics Group’s revenue was up 21.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.70 earnings per share. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1.92 EPS for the current fiscal year.

Analyst Ratings Changes

TMDX has been the subject of several recent analyst reports. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. TD Cowen reiterated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a report on Wednesday, July 1st. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 target price on shares of TransMedics Group in a research note on Tuesday, June 30th. UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Tuesday, May 26th. Finally, Wall Street Zen lowered TransMedics Group from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $134.50.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.